GUARDANT HEALTH, INC. (GH) Quick Ratio
- Quick ratio · latest quarter: Value 3.53×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 3.53× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $1.20B ÷ $338.96M ≈ 3.53× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 1.20B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 338.96M USD | Liabilities, Current |
| Cash and equivalents | 1.05B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 0.00 USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 144.25M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 105.46M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.20B | $338.96M | $1.05B | $0.00 | $144.25M | $105.46M | 3.53× |
| 2026-03-31 | $1.24B | $292.14M | $989.29M | $113.47M | $137.40M | $83.85M | 4.25× |
| 2025-12-31 | $1.34B | $302.73M | $378.20M | $823.39M | $137.85M | $85.88M | 4.42× |
| 2025-09-30 | $695.60M | $236.92M | $580.01M | $0.00 | $115.58M | $90.49M | 2.94× |
| 2025-06-30 | $759.39M | $238.43M | $629.14M | $0.00 | $130.25M | $84.06M | 3.18× |
| 2025-03-31 | $814.00M | $225.75M | $698.57M | $0.00 | $115.43M | $77.26M | 3.61× |
| 2024-12-31 | $950.23M | $225.58M | $525.54M | $314.44M | $110.25M | $71.08M | 4.21× |
| 2024-09-30 | $984.19M | $197.34M | $585.02M | $310.70M | $88.47M | $72.30M | 4.99× |
| 2024-06-30 | $1.03B | $201.57M | $933.69M | $0.00 | $100.52M | $66.98M | 5.13× |
| 2024-03-31 | $1.11B | $220.01M | $1.03B | $0.00 | $84.56M | $62.99M | 5.06× |
| 2023-12-31 | $1.26B | $205.92M | $1.13B | $35.10M | $88.78M | $61.95M | 6.11× |
| 2023-09-30 | $1.24B | $226.75M | $457.34M | $697.48M | $88.80M | $77.04M | 5.48× |
| 2023-06-30 | $1.31B | $200.93M | $271.07M | $953.78M | $86.47M | $60.53M | 6.53× |
| 2023-03-31 | $1.02B | $204.16M | $223.64M | $713.38M | $87.20M | $46.47M | 5.02× |
| 2022-12-31 | $1.11B | $193.22M | $141.65M | $869.58M | $97.26M | $51.60M | 5.74× |
| 2022-09-30 | $1.04B | $175.12M | $158.31M | $799.73M | $86.20M | $63.05M | 5.96× |
| 2022-06-30 | $948.97M | $167.75M | $215.17M | $638.52M | $95.28M | $59.89M | 5.66× |
| 2022-03-31 | $1.05B | $228.81M | $573.60M | $388.66M | $84.33M | $36.61M | 4.57× |
| 2021-12-31 | $1.03B | $194.69M | $492.20M | $440.55M | $97.65M | $30.67M | 5.29× |
| 2021-09-30 | $1.55B | $102.30M | $832.37M | $653.60M | $60.74M | $24.74M | 15.12× |
| 2021-06-30 | $1.85B | $96.61M | $938.59M | $853.07M | $53.67M | $26.49M | 19.10× |
| 2021-03-31 | $1.99B | $95.50M | $869.37M | $1.07B | $48.04M | $28.88M | 20.82× |
| 2020-12-31 | $1.85B | $66.81M | $832.98M | $961.90M | $53.30M | $22.72M | 27.66× |
| 2020-09-30 | $1.05B | $71.97M | $142.94M | $870.46M | $36.26M | $27.73M | 14.59× |
| 2020-06-30 | $978.85M | $70.05M | $164.67M | $773.16M | $41.02M | $20.35M | 13.97× |
| 2020-03-31 | $568.11M | $82.32M | $152.24M | $367.85M | $48.02M | $25.15M | 6.90× |
| 2019-12-31 | $570.79M | $72.73M | $143.23M | $379.57M | $47.99M | $15.18M | 7.85× |
| 2019-09-30 | $562.64M | $67.82M | $147.19M | $375.77M | $39.69M | $14.76M | 8.30× |
| 2019-06-30 | $585.99M | $57.05M | $174.65M | $370.97M | $40.36M | $14.18M | 10.27× |
| 2019-03-31 | $495.85M | $48.19M | $153.79M | $313.07M | $28.99M | $10.26M | 10.29× |
| 2019-01-01 | (m) | (m) | (m) | (m) | $40.60M | (m) | (m) |
| 2018-12-31 | $454.65M | $46.94M | $140.54M | $278.42M | $35.69M | $9.14M | 9.68× |
| 2018-09-30 | $285.98M | $32.05M | $113.96M | $157.38M | $14.64M | $7.08M | 8.92× |
| 2017-12-31 | $234.11M | $19.63M | $72.28M | $149.04M | $12.79M | $7.29M | 11.93× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| QUEST DIAGNOSTICS INC (DGX) | United States | $26.096B | 22.09 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |